Could this small-cap biotech stock beat the UKOG share price?

UK Oil & Gas plc (LON: UKOG) is a growth investors’ favourite, but we shouldn’t overlook the potential for biotechnology profits too.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

sdf

In all the years I’ve been following the stock market, the key sectors for those looking for high-flying growth shares have been oil exploration and technology — with biotechnology capturing a lot of investor cash in that latter set.

I’ve liked Oxford BioMedica (LSE: OXB) for some time as a ‘blue sky’ candidate — a company that isn’t currently making any profits, but looks like it has strong potential. Since I last looked at the gene and cell therapy researcher in February, the share price has gained another 48%, and it added a couple of percent Tuesday after the firm announced its latest success.

Novartis has received approval for its CAR-T cell therapy, Kymriah, for the treatment of various kinds of lymphoblastic leukaemia and lymphoma, and Oxford BioMedica is “the sole manufacturer of the lentiviral vector that encodes the CD19-directed chimeric antigen receptor in Kymriah.” I’m not going to pretend I know what that means, but Oxford BioMedica signed an agreement last year for the supply of lentiviral vectors to Novartis. The company says it could potentially receive more than $100m for this over three years, coupled with currently undisclosed royalties — and I do know what that means.

First-half results from Oxford BioMedica are due on 13 September, and what I’ll mostly be checking is the firm’s current liquidity and its potential for some actual profit this year. Forecasts suggest around £9m in pre-tax profit, though at this stage that’s not a long way above zero and I’ve seen early blue sky profits like this subsequently reversed. 

The company had £14.3m in cash at 31 December 2017, and enjoyed a £20.5m placing in March, so funding is still vitally important. But as long as that looks good, I still see an attractive growth candidate here.

Beating oil?

UK Oil & Gas (LSE: UKOG) has followed a typical oil explorer trajectory. The potential hydrocarbon wealth at the Horse Hill operation near Gatwick, which the firm shares with a number of other prospectors, led to a pile-in from investors in mid-2017. But as is often the case, the excitement turned out to not have considered all the risks, and early flow tests encountered difficulties.

As I said when I last looked at UKOG at the end of June, the company’s new planned flow tests could make a big difference. The balance between funding the exploratory work and the timescale to actual commercial pumping tends to be critical for small operators, especially those not making any profit.

In early August we had the results, with implied stable daily pumped rates of 401 and 414 barrels of oil from the firm’s Portland tests, which continued for six hours and two hours respectively. The report also told of “solution gas rates of around 41,000 cu ft per day.

Chief executive Stephen Sanderson described this as “excellent short-term high-rate test results,” pointing out that “potential future near-term cash flow from the Portland is very important to UKOG.” And that is critical — the long-term potential (with long-term testing set to happen soon) won’t be achieved if the company doesn’t make it financially.

I reckon the signs are indeed turning positive for UKOG, but right now my money would be on Oxford BioMedica — it looks like considerably lower risk to me, but still with serious growth potential. 

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Alan Oscroft has no position in any of the shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Middle-aged white man wearing glasses, staring into space over the top of his laptop in a coffee shop
Investing Articles

How much passive income could a £20,000 ISA provide in a year?

A diversified portfolio of high-yield FTSE shares can build a large and reliable passive income over time, as Royston Wild…

Read more »

Three generation family are playing football together in a field. There are two boys, their father and their grandfather.
Investing Articles

See how much an investor needs in an ISA to fund an £888 monthly passive income

Harvey Jones grabs his calculator to work out how much money people need to generate a decent passive income in…

Read more »

UK financial background: share prices and stock graph overlaid on an image of the Union Jack
Value Shares

The BP share price is climbing – see how much £10k invested 1 month ago is worth now

It's been a tough few years for the BP share price. Harvey Jones examines whether the FTSE 100 oil giant…

Read more »

Santa Clara offices of NVIDIA
Investing Articles

Nvidia stock has soared 1,471% in 5 years. Here’s how I’m hunting for the next Nvidia!

Nvidia stock has put in a stunning performance over the past five years. This writer tries to apply some lessons…

Read more »

A young woman sitting on a couch looking at a book in a quiet library space.
Investing Articles

If someone decided to start buying shares with £10k a year ago, here’s what they could be sitting on now!

If someone had started buying shares a year ago with £10k, what might have happened? Our writer outlines some factors…

Read more »

Rolls-Royce's Pearl 10X engine series
Investing Articles

The Rolls-Royce share price is close to an all-time record. Could it still be a bargain?

The Rolls-Royce share price has been punching out the lights of late. Our writer thinks things could get even better…

Read more »

4 Teslas in a parking lot at a charger station
Investing Articles

The Tesla share price slips further — how much would £10k invested at the start of the year be worth now?

The Tesla share price remains under pressure, with risks mounting from multiple directions. Here’s what a £10,000 investment would be…

Read more »

British pound data
Investing Articles

The Ocado share price is a sea of red! Time to cut my losses?

Every time Harvey Jones checks out the Ocado share price, he sees red. Will it ever stop falling and leaving…

Read more »